

# Emilio Vargas

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9493016/emilio-vargas-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55  
papers

1,749  
citations

19  
h-index

41  
g-index

63  
ext. papers

2,110  
ext. citations

4.9  
avg, IF

4.37  
L-index

#	Paper	IF	Citations
55	Reply: Preventing Bleeding With Direct-Acting Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, e129	15.1	
54	Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2987-3001	15.1	12
53	Benefits of the application of heat and pressure on peripheral venous cannulation in adults: A randomized controlled trial. <i>Journal of Advanced Nursing</i> , <b>2021</b> , 77, 1533-1545	3.1	
52	Phlebotonics for venous insufficiency. <i>The Cochrane Library</i> , <b>2020</b> , 11, CD003229	5.2	8
51	Chiral bioanalytical methods in bioequivalence studies of intravenous vs. oral formulations of ibuprofen. <i>Chirality</i> , <b>2020</b> , 32, 1169-1177	2.1	1
50	Effect of enantiomerism on the bioequivalence of a new ibuprofen 600-mg tablet formulation obtained by roller compaction. <i>Chirality</i> , <b>2020</b> , 32, 185-190	2.1	1
49	Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect?. <i>European Journal of Clinical Pharmacology</i> , <b>2019</b> , 75, 647-654	2.8	2
48	Causes of Death in Patients with Venous Thromboembolism Anticoagulated with Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2018</b> , 44, 377-387	5.3	5
47	Adverse drug reactions in neonates: a prospective study. <i>Archives of Disease in Childhood</i> , <b>2016</b> , 101, 371-6	2.2	13
46	Phlebotonics for venous insufficiency. <i>The Cochrane Library</i> , <b>2016</b> , 4, CD003229	5.2	50
45	Causes of Death in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2508-2521	15.1	142
44	Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 633-44	3.8	14
43	Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2015</b> , 20, 490-500	2.6	41
42	Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives. <i>European Journal of Haematology</i> , <b>2015</b> , 95, 389-404	3.8	56
41	Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2014</b> , 134, 774-82	8.2	88
40	Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain. <i>Pharmacoeconomics</i> , <b>2014</b> , 32, 919-36	4.4	15
39	Specific antidotes in development for reversal of novel anticoagulants: a review. <i>Recent Patents on Cardiovascular Drug Discovery</i> , <b>2014</b> , 9, 2-10		40

38	Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. <i>Vascular Health and Risk Management</i> , <b>2014</b> , 10, 627-39	4.4	16
37	Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. <i>Vascular Health and Risk Management</i> , <b>2013</b> , 9, 207-28	4.4	18
36	Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. <i>Thrombosis</i> , <b>2013</b> , 2013, 640723		122
35	Response Letter to Malafarina and Colleagues. <i>Journal of the American Geriatrics Society</i> , <b>2012</b> , 60, 807-807	3.0	1
34	Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. <i>BMJ, The</i> , <b>2012</b> , 344, e3675	5.9	160
33	Discovery of anticoagulant drugs: a historical perspective. <i>Current Drug Discovery Technologies</i> , <b>2012</b> , 9, 83-104	1.5	74
32	Risk of cerebrovascular accident associated with use of antipsychotics: population-based case-control study. <i>Journal of the American Geriatrics Society</i> , <b>2011</b> , 59, 1182-7	5.6	27
31	New parenteral anticoagulants in development. <i>Therapeutic Advances in Cardiovascular Disease</i> , <b>2011</b> , 5, 33-59	3.4	38
30	Truncated area under the urinary excretion rate curve in the evaluation of alendronate bioequivalence after a single dose in healthy volunteers. <i>Arzneimittelforschung</i> , <b>2009</b> , 59, 397-402		3
29	Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient?. <i>Journal of Thrombosis and Haemostasis</i> , <b>2009</b> , 7, 2149-50	15.4	5
28	Rivaroxaban versus enoxaparin after total knee arthroplasty. <i>Lancet, The</i> , <b>2009</b> , 374, 682; author reply 683	4.0	8
27	Effect of drug-test interactions on length of hospital stay. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2007</b> , 16, 39-45	2.6	2
26	Drug evaluation and approval process in the European Union. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 55, 12-4		8
25	Phlebotonics for venous insufficiency. <i>Cochrane Database of Systematic Reviews</i> , <b>2005</b> , CD003229		37
24	A health system program to reduce work disability related to musculoskeletal disorders. <i>Annals of Internal Medicine</i> , <b>2005</b> , 143, 404-14	8	33
23	Food-drug interactions in the summary of product characteristics of proprietary medicinal products. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 61, 77-83	2.8	17
22	Bioequivalence study of two different tablet formulations of carvedilol in healthy volunteers. <i>Arzneimittelforschung</i> , <b>2005</b> , 55, 212-7		6
21	Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers. <i>Current Therapeutic Research</i> , <b>2004</b> , 65, 34-46	2.4	9

20	Effect of adverse drug reactions on length of stay in surgical intensive care units. <i>Critical Care Medicine</i> , <b>2003</b> , 31, 694-8	1.4	48
19	Disparate results in studies of methotrexate plus corticosteroids in the treatment of giant cell arteritis: comment on the article by Hoffman et al. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 48, 1158-9		6
18	Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 49, 64-70		128
17	A new high-absorption-rate Paracetamol 500-mg formulation: a comparative bioavailability study in healthy volunteers. <i>Current Therapeutic Research</i> , <b>2003</b> , 64, 401-11	2.4	9
16	Pharmacokinetic Study of a New Ibuprofen 600mg plus Codeine 30mg Combination versus Ibuprofen or Codeine Alone in Single Oral Doses in Healthy Volunteers. <i>Clinical Drug Investigation</i> , <b>2002</b> , 22, 41-49	3.2	2
15	Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. <i>Annals of Internal Medicine</i> , <b>2001</b> , 134, 106-14	8	289
14	Comparative Single-Dose Bioavailability Study of Two Oral Formulations of Ibuprofen in Healthy Volunteers. <i>Clinical Drug Investigation</i> , <b>2001</b> , 21, 383-389	3.2	3
13	Modification of Albumin Use Pattern After an Educational Intervention. <i>Disease Management and Health Outcomes</i> , <b>2000</b> , 8, 43-50		1
12	Acute myocardial infarction associated with sildenafil. <i>Lancet, The</i> , <b>1998</b> , 352, 1936-7	40	3
11	Effect of adverse drug reactions on length of stay in intensive care units. <i>Clinical Drug Investigation</i> , <b>1998</b> , 15, 353-60	3.2	18
10	Use of Intravenous Omeprazole in a University Hospital. <i>Journal of Pharmacy Technology</i> , <b>1997</b> , 13, 32-35.6		
9	Effect of Drug Interactions on the Development of Adverse Drug Reactions. <i>Clinical Drug Investigation</i> , <b>1997</b> , 13, 282-289	3.2	6
8	Acute cerebellopathy as a probable toxic effect of flucytosine. <i>European Journal of Clinical Pharmacology</i> , <b>1997</b> , 51, 505-6	2.8	5
7	Use of albumin in two Spanish university hospitals. <i>European Journal of Clinical Pharmacology</i> , <b>1997</b> , 52, 465-70	2.8	23
6	Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 358-70		67
5	Adverse Drug Reactions in a Cardiology Department. <i>Clinical Drug Investigation</i> , <b>1996</b> , 12, 46-52	3.2	1
4	Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer. <i>European Journal of Clinical Pharmacology</i> , <b>1991</b> , 40, 525-7	2.8	2
3	Polymorphic oxidation of debrisoquine in lung cancer patients. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1991</b> , 27, 158-61		17

2	Polymorphic oxidation of debrisoquine in women with breast cancer. <i>Oncology</i> , <b>1991</b> , 48, 107-10	3.6	21
1	Polymorphic oxidation of debrisoquine in bladder cancer. <i>Annals of Medicine</i> , <b>1990</b> , 22, 157-60	1.5	13